ArticleMolecular cancer therapeutics2014
Surface-modified nanoparticles enhance transurothelial penetration and delivery of survivin siRNA in treating bladder cancer.
Article in Molecular cancer therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 78 citations in OpenAlex.
- Localized nanomedicine for urologic cancers: anatomy-guided design and clinical translation.Materials today. Bio · 2026Review
- Nanotechnology-enabled precision strategies for bladder cancer: from in vitro diagnostics to in vivo therapy.Journal of nanobiotechnology · 2026Review
- Smart Physicochemical-triggered Chitosan-based Nanogels for siRNA Delivery and Gene Therapy: A Focus on Emerging Strategies and Paradigms for Cancer Therapy.Current medicinal chemistry · 2025Review
- Nanomedicine in Bladder Cancer Therapy.International journal of molecular sciences · 2024Review
- Local Drug Delivery in Bladder Cancer: Advances of Nano/Micro/Macro-Scale Drug Delivery Systems.Pharmaceutics · 2023Review
- The Progress of Chitosan-Based Nanoparticles for Intravesical Bladder Cancer Treatment.Pharmaceutics · 2023Review
- Inhibitor of apoptosis proteins as therapeutic targets in bladder cancer.Frontiers in oncology · 2023Review
- (Nano)platforms in bladder cancer therapy: Challenges and opportunities.Bioengineering & translational medicine · 2023Review
- Quercetin Loaded Cationic Solid Lipid Nanoparticles in a Mucoadhesive In Situ Gel-A Novel Intravesical Therapy Tackling Bladder Cancer.Pharmaceutics · 2022Article
- State-of-the-Art Advances of Nanomedicine for Diagnosis and Treatment of Bladder Cancer.Biosensors · 2022Review
- Nanoparticles-Based Strategies to Improve the Delivery of Therapeutic Small Interfering RNA in Precision Oncology.Pharmaceutics · 2022Review
- An Overview of siRNA Delivery Strategies for Urological Cancers.Pharmaceutics · 2022Review
- Application of nanotechnology in the diagnosis and treatment of bladder cancer.Journal of nanobiotechnology · 2021Review
- Multicellular Ovarian Cancer Model for Evaluation of Nanovector Delivery in Ascites and Metastatic Environments.Pharmaceutics · 2021Article
- Cannabidiol Effectively Promoted Cell Death in Bladder Cancer and the Improved Intravesical Adhesion Drugs Delivery Strategy Could Be Better Used for Treatment.Pharmaceutics · 2021Article
- Thymopentin alleviates premature ovarian failure in mice by activating YY2/Lin28A and inhibiting the expression of let-7 family microRNAs.Cell proliferation · 2021Article
- Strategies to Get Drugs across Bladder Penetrating Barriers for Improving Bladder Cancer Therapy.Pharmaceutics · 2021Review
- MicroRNA-146b-5p overexpression attenuates premature ovarian failure in mice by inhibiting the Dab2ip/Ask1/p38-Mapk pathway and γH2A.X phosphorylation.Cell proliferation · 2021Article
- Sustained-release Griffithsin nanoparticle-fiber composites against HIV-1 and HSV-2 infections.Journal of controlled release : official journal of the Controlled Release Society · 2020Article
- Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?Journal of experimental & clinical cancer research : CR · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Penetration of the bladder permeability barrier (BPB) is a major challenge when treating bladder diseases via intravesical delivery. To increase transurothelial migration and tissue and tumor cell uptake, poly(lactic-co-glycolic acid; PLGA) nanoparticles (NP) were modified by addition of a low molecular weight (2.5 or 20 kDa) positively charged mucoadhesive polysaccharide, chitosan, to the NP surface. In designing these NPs, we balanced the adhesive properties of chitosan with the release and bioactivity of the siRNA. Chitosan-functionalized NPs demonstrated increased binding to and uptake in intravesically instilled mouse bladders and human ureter at 10 times the level of unmodified NPs. Furthermore, we extended the bioactivity of survivin siRNA in vitro for up to 9 days and demonstrated a decrease in proliferation when using chitosan-modified NPs relative to unmodified NPs. In addition, treatment of xenograft tumors with chitosan-modified NPs that encapsulate survivin siRNA (NP-siSUR-CH2.5) resulted in a 65% reduction in tumor volume and a 75% decrease in survivin expression relative to tumors treated with blank chitosan NPs (NP-Bk-CH2.5). Our low molecular weight chitosan delivery system has the capacity to transport large amounts of siRNA across the urothelium and/or to the tumor site, thus increasing therapeutic response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.